# Treatment of Primary CNS Lymphoma

> **NCT01960192** · PHASE4 · UNKNOWN · sponsor: **Mingzhi Zhang** · enrollment: 50 (estimated)

## Conditions studied

- Primary CNS Lymphoma (PCNSL)

## Interventions

- **DRUG:** HD-MTX-Ara-C regimen
- **DRUG:** FVD regimen

## Key facts

- **NCT ID:** NCT01960192
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2016-06
- **Final completion:** 2020-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2015-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01960192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01960192, "Treatment of Primary CNS Lymphoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01960192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*